ES2602965T3 - Inhibidores de aril lactama quinasa - Google Patents

Inhibidores de aril lactama quinasa Download PDF

Info

Publication number
ES2602965T3
ES2602965T3 ES13744927.8T ES13744927T ES2602965T3 ES 2602965 T3 ES2602965 T3 ES 2602965T3 ES 13744927 T ES13744927 T ES 13744927T ES 2602965 T3 ES2602965 T3 ES 2602965T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
retention time
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13744927.8T
Other languages
English (en)
Spanish (es)
Inventor
Vivekananda M. Vrudhula
Senliang Pan
Ramkumar Rajamani
Susheel Jethanand NARA
Maheswaran Sivasamban KARATHOLUVHU
Tarun Kumar MAISHAL
Jonathan L. Ditta
Carolyn Diane Dzierba
Joanne J. Bronson
John E. Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2602965T3 publication Critical patent/ES2602965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13744927.8T 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa Active ES2602965T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US201261677856P 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors
US201313946344 2013-07-19
PCT/US2013/051831 WO2014022167A1 (en) 2012-07-31 2013-07-24 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2602965T3 true ES2602965T3 (es) 2017-02-23

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13744927.8T Active ES2602965T3 (es) 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa

Country Status (12)

Country Link
US (1) US8901305B2 (enExample)
EP (1) EP2880032B1 (enExample)
JP (1) JP2015528018A (enExample)
CN (1) CN104507941A (enExample)
AR (1) AR093758A1 (enExample)
BR (1) BR112015001890A2 (enExample)
CA (1) CA2880523A1 (enExample)
EA (1) EA201590268A1 (enExample)
ES (1) ES2602965T3 (enExample)
MX (1) MX2015000980A (enExample)
TW (1) TW201410676A (enExample)
WO (1) WO2014022167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
CA2944466C (en) * 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
CN112142655A (zh) * 2015-10-01 2020-12-29 百时美施贵宝公司 联芳基激酶抑制剂
US12636370B2 (en) * 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK0672031T3 (da) 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
ATE388946T1 (de) 2002-04-05 2008-03-15 Boehringer Ingelheim Pharma Cyanamide als reversible hemmer von cystein proteasen
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2007523109A (ja) * 2004-02-18 2007-08-16 エフ．ホフマン−ラ　ロシュ　アーゲー 複素環式Ｇａｂａ−Ａサブタイプ選択的レセプターモジュレーター
CA2570694A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007068465A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセット輸送体の調節剤
US20080040819A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treatment of schizophrenia and related disorders
EP2094682A2 (en) * 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
EP2552922A1 (en) * 2010-03-31 2013-02-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
HK1199814A1 (en) 2012-03-09 2015-07-24 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Also Published As

Publication number Publication date
JP2015528018A (ja) 2015-09-24
EP2880032B1 (en) 2016-10-05
EA201590268A1 (ru) 2015-05-29
AR093758A1 (es) 2015-06-24
CA2880523A1 (en) 2014-02-06
MX2015000980A (es) 2015-04-10
BR112015001890A2 (pt) 2017-07-04
CN104507941A (zh) 2015-04-08
US8901305B2 (en) 2014-12-02
TW201410676A (zh) 2014-03-16
US20140038999A1 (en) 2014-02-06
EP2880032A1 (en) 2015-06-10
WO2014022167A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
ES2885432T3 (es) Derivados de imidazol pentacíclicos condensados
KR102411532B1 (ko) 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물
JP6335172B2 (ja) テノホビルプロドラッグおよびその医薬用途
ES2582315T3 (es) Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma
US9120791B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
ES2624263T3 (es) Azaindoles en calidad de agentes antivirales del virus sincitial respiratorio
CA3093527A1 (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2021004547A1 (en) Heterocyclic compounds as inhibitors of hpk1
ES2685661T3 (es) Derivado de pirrolopirimidina
IL256375A (en) New histological histories, process for their preparation and pharmaceutical preparations containing them
CA3115643A1 (en) Amino acid compounds and methods of use
ES2642762T3 (es) Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
JP6487527B2 (ja) スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
CA2901868C (en) Dihydropyridazine-3,5-dione derivative
CN118434747A (zh) 一种含氮杂环化合物、其制备方法、中间体及应用
IL297969A (en) Treatment of respiratory diseases with amino acid compounds
RS61693B1 (sr) 4,6-supstituisani-pirazolo[1,5-a]pirazini kao inhibitori janus kinaze
JP7731895B2 (ja) モノアシルグリセロールリパーゼ調節因子
ES2987356T3 (es) Compuestos antiproliferación y usos de los mismos
ES2922029T3 (es) Análogos de hexahidropirimidina antimalaria
CA2880523A1 (en) Aryl lactam kinase inhibitors
CN118382625A (zh) 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
WO2022028598A1 (en) Atr inhibitors and uses thereof
CA2825906A1 (en) Compounds for the reduction of .beta.-amyloid production